Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …

Acute lymphoblastic leukaemia develops in both children and adults, with a peak incidence
between 1 year and 4 years. Most acute lymphoblastic leukaemia arises in healthy …

Cellular senescence contributes to Alzheimer's disease (AD) pathogenesis. An open-label,
proof-of-concept, phase I clinical trial of orally delivered senolytic therapy, dasatinib (D) and …

Cellular senescence is characterized by an irreversible cell cycle arrest and a pro‐
inflammatory senescence‐associated secretory phenotype (SASP), which is a major …

Opioids are a mainstay of acute pain management but can have many adverse effects,
contributing to problematic long-term use. Opioid tolerance (increased dose needed for …

Preclinical studies indicate an age-associated accumulation of senescent cells across
multiple organ systems. Emerging evidence suggests that tau protein accumulation, which …

Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults,
with an incidence of over 6500 cases per year in the United States alone. The hallmark of …

PURPOSE Despite contemporary treatment, up to 10% of children with acute lymphoblastic
leukemia still experience relapse. We evaluated whether a higher dosage of PEG …

The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has
been a model for cancer therapy development. Though most patients with CML have a …

Importance A randomized clinical trial is needed to determine whether the second-
generation Abl–tyrosine kinase inhibitor dasatinib is more effective than the first-generation …